SCG Cell Therapy

Hepatitis B
#Cell therapy #Phase I trial #SCG Cell Therapy #T cell receptor (TCR) #Viral hepatitis

T cell therapy for HBV shows promising antiviral activity

SCG Cell Therapy has announced late-breaking data from its Phase I trial of SCG101, a first-in-class autologous hepatitis B virus (HBV)-specific T-cell receptor-engineered T cell (TCR-T) therapy targeting hepatitis B surface antigen (HBsAg).   The data was presented at the 2024 AASLD Liver Meeting in San Diego, United… Read More

#Editor's Choice #News